### Johns Hopkins Engineering

### Immunoengineering

Immunoengineering Allergy and Autoimmunity
Introduction



# Learning Objectives

- Describe the autoimmune and allergic disease market and drug landscape
- Utilize engineering design principles to design diagnostic devices for allergy and autoimmune disease
- Describe the importance and limitations of the microbiota's role in autoimmune and allergic disease as a biomarker and potential new therapy
- Compare and contrast mammalian and bacterial cells as sources for genetically engineered therapeutics
- Compare and contrast biologic with biomaterial approaches to treat allergy and autoimmunity
- Describe several examples of biologics and biomaterials being developed as therapeutics for autoimmune and allergic diseases
- Utilize biologic and biomaterial design principles to develop solutions to autoimmune and allergic diseases

# Allergies

- 60 million people affected in the U.S.
- 6<sup>th</sup> leading cause of chronic illness in the U.S.
- Allergic Rhinitis \$11.2 billion in U.S. (much on prescription medications)

### NIH Designates \$42.7 Million for Food Allergy Research Consortium

Consortium Will Continue Seeking Food Allergy Treatment Strategies over Next Seven Years

March 29, 2017

The National Institutes of Health intends to award \$42.7 million over seven years to the Consortium of Food Allergy Research (CoFAR) of so it may continue evaluating new approaches to treat food allergy. Established in 2005, the CoFAR has been continuously funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH. The first year of funding has been awarded, and awards will be made in subsequent years based on the availability of funds.


### **Autoimmunity**

- 50 million people affected
- Costs up to \$50 billion in the U.S.


#### The Estimated Cost of Selected Autoimmune Diseases

Autoimmune Disease	Base Yr	Country	Indirect Costs	Direct Costs	Total Est'd Costs
Crohn's disease	2008	US			\$10.9-\$15.5 billion
Ulcerative colitis	2008	US	Est'd at 40 percent of direct costs	\$3.4–8.6 billion	\$8.1–\$14.9 billion
SLE	2008	US	\$8,659/pt/yr	\$12,643/pt/yr.	\$2.2-\$9.6 billion
MS	1994	US			\$6.8 billion
RA	2005	US	\$8.4 billion	\$10.9 billion	\$19.3 billion
Psoriasis	2010	US	\$4.5 billion	\$6.7 billion	\$11.2 billion
Scleroderma	1997	US			\$1.5 billion


### Lots of room for improvement



# Lots of room for improvement



### Clinical Trials



### Corporate activity







Sarah Buhr @sarahbuhr / Nov 17, 2015

Comment

On Thursday, Summit, New Jersey-based Celgene Corporation announced plans to acquire Delinia for an upfront \$300 million and an additional \$475 million in



**Sean Parker** • has been very philanthropic lately, particularly with life sciences research. Parker announced he'd given \$600 million to a foundation with his name on it this summer and \$24 million last December to establish an alleray

# Pandion raises \$58M for its autoimmune platform inspired by the tumor microenvironment

By JULIET PRESTON













